Rigel Pharmaceuticals Inc (RIGL) valuation
Rigel Pharmaceuticals P/E ratio history
Rigel Pharmaceuticals trades at 3.0 times its earnings over the last twelve months and 12.1 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $42.83 | $19.48 | 2.2 | 9.2 |
| Dec 31, 2024 | $16.82 | $0.99 | 17.0 | — |
| Dec 31, 2023 | $14.50 | -$1.44 | n/m | — |
| Dec 31, 2022 | $15.00 | -$3.44 | n/m | — |
| Dec 31, 2021 | $26.50 | -$1.10 | n/m | — |
| Dec 31, 2020 | $35.00 | -$1.80 | n/m | — |
| Dec 31, 2019 | $21.40 | — | n/m | — |
| Dec 31, 2018 | $23.00 | — | n/m | — |
| Dec 31, 2017 | $38.80 | — | n/m | — |
| Dec 31, 2016 | $23.80 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Rigel Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Rigel PharmaceuticalsRIGL | $949M | 3.0 | 12.1 | 3.4 |
| Si BoneSIBN | $942M | — | — | 4.4 |
| Oric PharmaceuticalsORIC | $957M | — | — | — |
| Cullinan TherapeuticsCGEM | $924M | — | — | — |
| IradimedIRMD | $980M | 41.0 | 32.4 | 11.4 |
| HealthstreamHSTM | $985M | 46.8 | 41.7 | 3.1 |
| SavaraSVRA | $988M | — | — | — |
| Kura OncologyKURA | $911M | — | — | 11.8 |
| Monte Rosa TherapeuticsGLUE | $909M | — | — | 31.6 |
| Peer median | 43.9 | 37.1 | 11.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: RIGL financials · RIGL returns
No forecast, no recommendation. This page describes Rigel Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.